Markc Markowski News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share:
Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue
Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer
MIAMI, May 24, 2021 (GLOBE NEWSWIRE) Veru Inc. (NASDAQ:VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that two abstracts were accepted for presentation at the 2021 American Society of Clinical Oncology Annual Meeting which will be held virtually from June 4-8, 2021. ....

United States , Mitchell Steiner , Carlo Palmieri , Sam Fisch , Markc Markowski , Company Sexual Health Business , Sexual Health Business , Johns Hopkins University School Of Medicine , University Of Liverpool , Exchange Commission , American Society Of Clinical Oncology Annual Meeting , Company Form , Company Female Health Division , Veru Inc , Sidney Kimmel Comprehensive Cancer Center , Clinical Oncology Annual Meeting , Discussion Session , Breast Cancer , Translational Oncology , Medical Oncologist , Assistant Professor , Johns Hopkins University School , Active Control , Female Health Company Division , Private Securities Litigation Reform Act , Investor Relations ,